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Abstract
Background: Radix Salvia miltiorrhiza (Danshen) has been used as a principal herb in treating cardiovascular
diseases in Chinese medicine. Salvianolic acid B (SA-B), a water-soluble active component of Danshen, was found to
have anti-myocardial ischemia (anti-MI) effect. This study aims to investigate mechanisms of SA-B on MI.
Methods: Five conventional Western medicines (isosorbide dinitrate, verapamil, propranolol, captopril and
trimethazine) with different mechanisms for treating cardiovascular diseases were selected as positive references to
compare with SA-B in changing of the metabolomic profiles in MI rats under treatment. Potential mechanisms of
SA-B were further investigated in H9C2 cell line.
Results: The metabolomic profiles between SA-B- and propranolol-treated MI rats were similar, since there was a
big overlap between the two groups in the PLS-DA score plot. Finally, it was demonstrated that SA-B exhibited a
protective effect on MI mainly by decreasing the concentration of cyclic adenosine monophosphate (cAMP) and
Ca
2+ and inhibiting protein kinase A (PKA).
Conclusion: SA-B and propanolol exhibited similar metabolomic profiles, indicating that the two drugs might have
a similar mechanism.
Background
Myocardial ischemia (MI) is characterized by ischemia
in the heart muscle. It is the most common cause of
death, and a major reason for hospital admissions [1]. In
MI, b-adrenoceptor is generally activated. Noradrenaline
binds to b-adrenoceptor to activate GS protein. Then,
adenylate cyclase (AC) is activated by GS protein, which
makes adenosine triphosphate (ATP) to be cyclic adeno-
sine monophosphate (cAMP). cAMP in turn activates
the cAMP-dependent protein kinase A (PKA). This
kinase phosphorylates several proteins related to excita-
tion-contraction coupling, such as L-type Ca
2+ channel
and phospholamban. The phosphorylation of L-type Ca
2
+ channel causes the Ca
2+ influx, leading to stronger
muscle contraction. The phosphorylation of phospho-
lamban accelerates Ca
2+ uptake into the sarcoplasmic
reticulum, increasing the rate and extent of muscle
relaxation [2,3].
b-adrenergic blockers such as propranolol [4] could
inhibit the activation of b-adrenoceptor and decrease
the concentration levels of cAMP, PKA and Ca
2+, lead-
ing to slow heart rate, decreased myocardial contracti-
lity, reduced cardiac output, and decreased myocardial
oxygen consumption. Besides, Western medicines with
other mechanisms of action, such as isosorbide dinitrate
(a vasodilator), verapamil (a calcium antagonist), capto-
pril (an angiotensin converting enzyme inhibitor) and
trimethazine (a fatty acid oxidation inhibitor), are also
commonly used in the prevention and treatment of MI.
In recent years, radix salvia miltiorrhiza (Danshen)i s
also widely used in Chinese medicine for the treatment
of cardiovascular diseases [5]. Danshen preparations in
China medicine, including Compound Danshen Tablet,
Compound Danshen Dripping Pill and Compound Dan-
shen Granule [6-8] have been developed with interest
from pharmaceutical industry.
Lam et al. [9,10] found that the dilator action of Dan-
shen on rat femoral artery was primarily produced by
the inhibition of Ca
2+ influx in the vascular smooth
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activate the endothelial nitric oxide synthase to induce
vasodilation and reduce blood pressure. However, there
is no final conclusion about mechanisms of Danshen.
Thus, most scientists hope to increase understanding of
mechanisms of Danshen by analyzing active components
of Danshen.P r e s e n t l y ,m a n ya c t i v ec o m p o n e n t sh a v e
been isolated and identified in Danshen,s u c ha st a n s h i -
none IIA, and salvianolic acid B (SA-B) [12-14].
SA-B, a water-soluble active component of Danshen,i s
effective for the protection of heart from ischemia [15].
Several possible cardio-protective effects were proposed,
including augmenting vascular endothelial growth factor
(VEGF) expression, promoting angiogenesis, recovering
the normal expressions of sarco/endoplasmic reticulum
ATPase 2a and phospholamban, and inhibiting the acti-
vation of platelet during myocardial ischemia and reper-
fusion [16-20].
Metabolomics is an emerging technique in the field of
“omics” research and it is the systematic study of meta-
bolites and its profile in a biological matrix, such as a
cell, organ or organism [21,22]. It aims to pinpoint
interesting metabolites that are related to disease or
drug treatment. Verhoeckx et al. [23] successfully inte-
grated the transcriptomic, proteomic and metabolomic
techniques to characterize inflammatory modulators on
the basis of their biological responses. Zilpaterol, a com-
pound originally developed as a b2-agonist but later spe-
cifically introduced as a growth-promoting agent,
showed a pattern of mRNA and lipid expression almost
identical to that showed by clenbuterol and salbutamol,
b2-agonists. In the same way, anti-MI drugs may be
categorized into classes based on their mechanisms of
action.
In this study, metabolomic approach was used to
explore potential mechanisms of SA-B by comparing
with five Western medicines (isosorbide dinitrate, vera-
pamil, propranolol, captopril and trimethazine) conven-




HPLC grade acetonitrile was purchased from JT Baker
(NJ, USA). Spectroscopic grade formic acid, leucine
enkephalin, dimethyl sulfoxide (DMSO) and 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
were purchased from Sigma/Aldrich (MO, USA). Dis-
tilled water was purified “in-house” using a Milli-Q20
system Millipore (MA, USA). SA-B was purchased from
the National Institute for the Control of Pharmaceutical
and Biological Products (Beijing, China). Isosorbide dini-
trate was purchased from Forward Co., Ltd (Shanghai,
China). Verapamil was purchased from Shanghai
Pharmaceutical (Group) Co., Ltd (Shanghai, China). Pro-
pranolol was purchased from Shanghai Xinpashi Phar-
maceutical Co., Ltd (Shanghai, China). Captopril was
purchased from Shanghai Hengshan Pharmaceutical
Factory (Shanghai, China). Trimethazine was purchased
from Servier Pharmaceutical Factory (Tianjin, China).
Fluo3/AM was purchased from Dojindo Laboratory
(Tokyo, Japan). cAMP-Glo™ Assay and PepTag
® Non-
Radio cAMP-Dependent Protein Kinase Assay were pur-
chased from Promega (Madison, USA).
Animals and drug administration
Fifty male Sprague-Dawley rats (185-215 g) were pur-
chased from the Slac Laboratory Animal Co., Ltd
(Shanghai, China). The animals were housed in stainless
steel metabolic cages under controlled conditions of
humidity (40-60%), temperature (23-27°C), and a 12 h
light-dark cycle. They were allowed free access to food
and tap water. MI model was induced by left anterior
descending coronary artery ligation [24]. The sham
group rats were given no ligation. Electrocardiograms
(ECG) were recorded by MPA 2000 Bio-signal Analysis
System (Alcott Biotech Co. Ltd., Shanghai, China) to
ascertain that the induction of MI was successful.
Among 42 MI rats, 36 were arbitrarily selected and
divided into six treatment groups (n = 6): SA-B (20 mg/
kg/d), isosorbide dinitrate (3 mg/kg/d), verapamil (6
mg/kg/d), propranolol (20 mg/kg/d), captopril (4 mg/kg/
d) and trimethazine (6 mg/kg/d). In sham (n = 6) and
MI (n = 6) groups, rats were received 0.2 mL of saline
each time. Drugs were weighed and crushed into fine
powder, which were orally administrated to rats with
saline for 7 days after modeling. Rats were fasted over-
night but with free access to water before their first
administration. Blood samples were collected from
ophthalmic venous plexus on the ninth day. The experi-
ment was carried out in accordance with the guidelines
of the Committee on the Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources
of Shanghai, China. The Animal Care and Use Commit-
tee of Second Military Medical University also approved
the study protocol.
Cell culture
The H9C2 cell line (Catalog No. GNR 5) was obtained
from the Cell Bank of the Chinese Academy of Sciences
and maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM; GIBCO, Paisley, UK) containing 10% fetal
bovine serum (FBS), penicillin-G (100 U/mL) and strep-
tomycin (100 U/mL), and incubated in a humidified
CO2 incubator (Sanyo, Japan) at 37°C with 5% CO2. The
cells were seeded at a density of 1 × 10
4/well in a 96-
well plate, and cultured for 12 h for adherence. Cells
were pre-treated with propranolol (0.01 mg/mL) or SA-
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h, and the cells were incubated in a Tri-Gas/CO2 incu-
bator (Sanyo, Japan) at 37°C with 5% CO2 and 95% N2
which was anoxic circumstance for 24 h. The cells were
incubated in a humidified CO2 incubator (Sanyo, Japan)
at 37°C with 5% CO2 as a control group. Ca
2+,c A M P
and PKA in the cells were measured. SA-B and propra-
nolol were dissolved in DMSO. Appropriate amount of
DMSO was also added to control media so that the
same final concentration of DMSO (less than 0.1%) can
be kept in all groups.
Metabolomics
A blood sample (1 mL) from each rat was collected and
kept in 2.5 mL heparin-coated tubes. These samples
were centrifuged at 2789.1 × g for 10 min at 4°C, and
the supernatants were collected. Acetonitrile (300 μL)
was added to the supernatant (100 μL). The mixture
was shaken vigorously for 30 s and centrifuged at 9562.5
× g for 10 min at 4°C. After centrifugation, the superna-
tant was analyzed on an ACQUITY™ UPLC system
coupled to a Micromass Q-Tof Micro™ (Waters MS
Technologies, Manchester, UK) equipped with an elec-
trospray ionization source. A 2.1 mm i.d. × 100 mm
ACQUITY™ 1.7 μm column (Waters, Milford, MA,
USA) was used. The column was maintained at 45°C.
Mobile phase A was formic acid (0.1%) in water; mobile
phase B was formic acid (0.1%) in acetonitrile; injection
volume was 5 μL; flow rate was 400 μL/min. The gradi-
ent duration program was: 0-1.5 min, 5% of B; 1.5-9
min, 5-100% of B; 9-14 min wash with 100% of B; and a
3 min recycle time. The parameters of mass detection
were: desolvation gas at 400 L/h; cone gas at 20 L/h;
desolvation temperature at 250°C; source temperature at
100°C; capillary voltage at 3000 V; cone voltage at 30 V;
collision energy at 5 eV, while it was set at 20 eV in
MS/MS mode to identify potential biomarkers. The data
acquisition rate was set as 0.4 s, with 0.1 s inter-scan
delay. Lock spray was used to calibrate accuracy of
mass. Leucine enkephalin was used as the lock mass
(m/z 556.2771 in the positive mode, and 554.2615 in the
negative mode). Data were collected in the continuum
mode and averaged over 10 scans. The lock spray fre-
quency was set at 10 s. Full scan mass range of 50-1000
m/z was acquired.
Cell viability
Cell viability was assessed by the MTT assay [25]. The
cells were treated with SA-B at concentrations of
0.0001, 0.001, 0.01 and 0.1 mg/mL for 24 h. Then, the
optical density (OD) values of samples were measured
using a microplate reader (Thermo Lab systems, Shang-
hai, China) at 570 nm (630 nm as a reference).
Measurement of calcium
The Ca
2+-sensitive was detected by dyeing with fluo-3/
AM [26]. The changes of Ca
2+ in cells were examined
by flow cytometry (BD Biosciences, USA).
Measurement of cAMP
The cAMP-Glo™ assay was used to monitor changes in
cAMP concentrations [27]. The luminescence was mea-
sured by the plate-reading luminometer (Thermo Lab
systems, Shanghai, China).
Determination of PKA activity
The activity of PKA was detected by non-radioactive Pep-
Tag PKA assay kit (Promega, Madison, USA) with dye-
labeled Kemptide as substrate according to the manufac-
turer’s protocol [28]. The cells were first homogenized in
a cold PKA extraction buffer. After centrifugation, the
supernatants were collected for the determination.
Data processing
T h es p e c t r a ld a t aw e r ee x p o r t e db yM i c r o m a s sM a r k e r -
Lynx™ applications manager version 4.1 software
(Waters Corporation, Milford, MA, USA). The raw data
of each sample was normalized to total area to correct
for the MS response shift from the first injection to the
last injection due to the long duration, overnight or
longer, of an LC-MS analysis. The sum of the ion peak
area within each sample was set at 10,000. After proces-
sing, partial least squares discriminant analysis (PLS-DA)
was used for analysis of metabolite profiles, which was
performed by the SIMCA-P software version 11 (Ume-
trics AB, Umeå, Sweden). In cell culture, each assay was
performed in triplicate and repeated three times. The
data were expressed as mean ± standard deviation (SD).
The significance was tested by one-way analyses of var-
iance (ANOVA) of the SPSS 13.0 for Windows (SPSS
Inc., Chicago, IL, USA), followed by the Duncan post hoc
test. P values less than 0.05 were considered significant.
Results and discussion
This study aims to investigate mechanisms of SA-B on
MI. Firstly, metabolomics in combination with multi-
variate statistical analysis was used to display potential
mechanisms of SA-B by comparing with five Western
medicines (isosorbide dinitrate, verapamil, propranolol,
captopril and trimethazine) conventionally used for the
treatment of cardiovascular diseases. Secondly, the
potential mechanisms of SA-B suggested by the metabo-
lomic study were further investigated in H9C2 cell line.
Metabolomics
In our previous study [29], a total of 2700 ions were
detected in metabolic profile of rats; 160 out of 2700
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with sham rats; 22 out of 160 ions were identified as
biomarkers of MI, including 15(S)-HETE, 2’,3’-Cyclic
AMP, dihydrosphingosine, 5-phosphoribosylamine, phy-
tosphingosine, L-isoleucyl-L-proline, 2’,3’-Cyclic GMP,
1-phenylethylamine, thromboxane B2, xanthine, hypox-
anthine, inosine, L-homoserine, carnosine, allantoin, L-
valine, L-phenylalanine, dihydrobiopterin, 2-oxoisoca-
proic acid, L-isoleucine, L-tryptophan and glyceralde-
hydes. In addition, SA-B was also found to be effective
for treating MI [8]. The present study revealed the anti-
MI effect of SA-B in more detail.
Anti-myocardial ischemia effect of SA-B
PLS-DA model [29] was built based on the significantly
changed ions (Top 160) observed in MI to evaluate the
protective effects of SA-B on MI. The PLS-DA score
plot (Figure 1A) showed that sham, MI and SA-B-trea-
ted rats were classified, and the SA-B-treated rats were
much closer to the sham rats than the MI rats, suggest-
ing that SA-B had a positive impact on repairing the
abnormal metabolic profiles induced by MI. To validate
the result statistically, the PLS-DA model was validated
by permutation test (n = 100) (Figure 1B). Generally,
Q
2-intercept in permutation test should be less than
0.05. The intercept value of Q
2 for this model was
-0.315, which meant no overfitting.
The mean levels of 22 identified MI biomarkers in
SA-B-treated rats were calculated to further evaluate the
regulations of SA-B. As shown in Table 1, levels of 18
biomarkers in SA-B-treated rats were statistically
reversed by compared with those in MI rats (P <0 . 0 5 ,
SA-B-treated groups versus MI group) [8]. The result
indicated that SA-B could regulate the abnormal meta-
bolites induced by MI.
Potential mechanisms of SA-B
In order to investigate the mechanisms of SA-B, we
selected five Western medicines (isosorbide dinitrate,
verapamil, propranolol, captopril and trimethazine) with
different mechanisms for treating MI as positive refer-
ences. PLS-DA model [29] was established based on the
global metabolomic profile of MI rats to compare the
influences of SA-B and five Western medicines. The
PLS-DA score plot (Figure 2) showed five Western med-
icine-treated groups were separated and the SA-B-trea-
ted group overlapped with the propranolol-treated
group (each symbol in the plot represents a sample),
indicating that the metabolomic profile of SA-B-treated
rats was similar with that of propranolol-treated rats.
Model validation with permutation test (n = 100) gener-
ated intercepts of Q
2 = -0.301, which suggested there
was no overfitting. The result indicated that SA-B and
propanolol might have a similar mechanism in treating
MI, since the drugs with the same mechanism showed
similar effects on the metabolomic profile [23].
By monitoring the changes of the 22 biomarkers after
administration, the regulations of SA-B and propranolol
were further compared. As aforementioned, 18 biomar-
kers were regulated by SA-B (P < 0.05, SA-B-treated
group versus MI group) (Table 1). Herein, we found
that levels of 21 biomarkers were reversed in proprano-
lol-treated rats by compared with those in MI rats (P <
0.05, propranolol-treated group versus MI group) (Table
1) [29]. The results further suggested that SA-B and
propranolol had similar regulations on biomarkers of
MI rats, indicating they might have a similar
mechanism.
Validation of mechanisms of SA-B in H2C2 cell line
As aforementioned, propranolol [4] could inhibit the
activation of b-adrenoceptor and decrease the concen-
tration levels of cAMP, PKA and Ca
2+, leading to slow
heart rate, decreased myocardial contractility, reduced
cardiac output, and decreased myocardial oxygen con-
sumption. In order to prove the propranolol-like effect
of SA-B, we tested whether SA-B could block b-adreno-
ceptor directly. Unfortunately, specific binding of SA-B
to b-adrenoceptor was not found in our early study (not
Figure 1 (a) PLS-DA score plot of the metabolic profiles
obtained from 6 sham rats (■), 6 MI rats with no treatment
(red diamond symbol), and 6 MI rats with SA-B treatment (blue
triangle symbol).( R
2X = 0.798, R
2Y = 0.975, Q
2 = 0.858, A = 4, N =
18, K = 160); (b) Validation plot obtained from permutation test (n =
100). R
2 is the explained variance, and Q
2 is the predictive ability of
the model.
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Biomarkers Sham group MI group SA-B group Propranolol group P value
Mean ± SD
a Mean ± SD Mean ± SD Mean ± SD SA-B vs. MI Propranolol vs.M I
Allantoin 23.87 ± 4.14 0.00 ± 0.00 20.32 ± 5.36 23.16 ± 8.17 0.000 0.000
1-Phenylethylamine 4.13 ± 1.88 23.66 ± 1.33 12.61 ± 0.96 9.42 ± 1.36 0.001 0.000
Hypoxanthine 0.00 ± 0.00 14.72 ± 14.01 6.68 ± 2.86 0.00 ± 0.00 0.001 0.000
L-Valine 37.98 ± 3.80 13.17 ± 2.14 22.75 ± 4.25 29.41 ± 6.31 0.002 0.001
L-Isoleucine 122.84 ± 21.91 39.18 ± 2.37 92.59 ± 12.26 139.28 ± 26.48 0.001 0.000
Carnosine 16.18 ± 2.70 0.00 ± 0.00 22.13 ± 04.27 19.35 ± 2.34 0.000 0.000
L-isoleucyl-L-Proline 28.69 ± 3.90 79.23 ± 21.02 52.15 ± 14.06 41.32 ± 20.49 0.027 0.011
Phytosphingosine 16.74 ± 1.89 82.93 ± 10.12 32.17 ± 6.29 41.38 ± 5.44 0.000 0.000
Dihydrosphingosine 26.02 ± 0.99 146.98 ± 15.82 52.18 ± 11.40 31.37 ± 7.14 0.001 0.000
2’,3’-Cyclic GMP 6.30 ± 0.81 37.05 ± 5.97 15.16 ± 3.49 11.32 ± 2.40 0.001 0.000
2’,3’-Cyclic AMP 30.33 ± 1.78 190.63 ± 16.91 153.21 ± 19.48 51.43 ± 8.46 0.008 0.000
Dihydrobiopterin 42.64 ± 4.78 8.23 ± 3.82 19.18 ± 8.31 39.27 ± 8.19 0.015 0.000
Xanthine 0.00 ± 0.00 25.94 ± 6.39 24.13 ± 7.51 0.00 ± 0.00 0.805 0.000
Inosine 0.00 ± 0.00 12.84 ± 3.49 12.03 ± 0.89 0.00 ± 0.00 0.913 0.000
Glyceraldehyde 189.71 ± 13.83 31.23 ± 2.72 99.30 ± 9.47 159.29 ± 12.69 0.000 0.000
L-Phenylalanine 14.65 ± 4.69 0.00 ± 0.00 5.34 ± 2.06 9.28 ± 2.44 0.000 0.000
L-Tryptophan 64.74 ± 12.98 20.06 ± 1.15 77.27 ± 2.40 59.45 ± 5.46 0.000 0.000
2-oxoisocaproic acid 27.85 ± 3.98 6.13 ± 1.23 17.33 ± 3.54 29.75 ± 4.94 0.000 0.000
5-Phosphoribosylamine 87.81 ± 4.96 211.14 ± 15.24 203.47 ± 10.26 129.32 ± 24.94 0.871 0.002
15(S)-HETE 0.00 ± 0.00 243.89 ± 99.98 71.67 ± 4.40 0.00 ± 0.00 0.001 0.000
Thromboxane B2 2.87 ± 1.95 18.27 ± 2.92 11.03 ± 0.64 9.42 ± 3.38 0.002 0.001
a Mean peak areas of MI biomarkers in different groups were calculated to reveal the beneficial effects of SA-B and propranolol; SD denotes standard deviation.
Figure 2 PLS-DA score plot of the metabolic profiles obtained from all drug-treated rats: (+) SA-B, (■)p r o p r a n o l o l( Δ) isosorbide
dinitrate, (○) trimethazine, (*) verapamil, and (▲) captopril.( R
2Y = 0.61, R
2X = 0.833, Q
2 = 0.512, A = 5, N = 36, K = 2700).
Lu et al. Chinese Medicine 2012, 7:6
http://www.cmjournal.org/content/7/1/6
Page 5 of 8published). In this study, we focused on the influences
of SA-B and propranolol on the downstream regulation
in b-adrenoceptor signaling pathway. The effects of SA-
B on the levels of on cAMP, PKA and Ca
2+ in cells
were investigated by H9C2 cell line, which is a commer-
cially available myogenic cell line derived from embryo-
nic rat heart ventricle [30] and is widely accepted as a
substitute for rat cardiomyocyte in in vitro study [31].
The viability of H9C2 cells was not affected signifi-
cantly by pretreatment with SA-B up to 0.1 mg/mL for
24 h (Figure 3), indicating that SA-B did not cause
damage to H9C2 cells. The results of Ca
2+,c A M Pa n d
PKA assays showed that SA-B significantly decreased
Ca
2+ concentration in anoxic H9C2 cells (Figure 4). We
suggested that SA-B might have a strong effect on the
regulation of Ca
2+ concentration even at a very low
dosage (0.001 mg/mL). We also found that both SA-B
and proprannolol significantly inhibited the increased
levels of cAMP induced by anoxia (Figure 5). SA-B
decreased cAMP concentration in a concentration-
dependent manner. As shown in Figure 6, PKA activity
was increased in anoxic cells, but significantly decreased
by SA-B and proprannolol treatment. In addition, there
was also no significant difference among these three SA-
B-treated groups. These results showed that SA-B could
decrease the concentration of Ca
2+ and inhibit the acti-
vation of PKA induced by anoxia at a very low dosage
(0.001 mg/mL), but required a high dosage (0.1 mg/mL)
to decrease the concentration of cAMP. The cell experi-
ments demonstrated that SA-B had a similar role in reg-
ulation of concentrations of Ca
2+,c A M Pa n da c t i v i t yo f
PKA as proprannolol.
Our previous studies suggested that the metabolomic
profile was changed in MI rats [29], and SA-B could
reverse the levels of most MI biomarkers [8]. The pre-
sent study indicated that SA-B- and propanolol-treated
rats had similar metabolomic profiles, which suggested
that the two drugs might have a similar mechanism in
treating MI, since the drugs with the same mechanism
showed similar effects on the metabolomic profile. The
hypothesis that SA-B and propranolol had a similar
mechanism in treating MI was supported by these
experiments. Although no evidence showed that SA-B
could block b-adrenoceptor directly, the cell experi-
ments demonstrated that SA-B showed a similar role in
regulation of concentrations of Ca
2+, cAMP and activity
of PKA as proprannolol. While the drug action of the
metabolites of SA-B is still under investigation, our
results suggest that metabolomics is a good analytical
method for understanding mechanisms of SA-B.
Conclusions
SA-B is a water-soluble active component of Danshen,
and is potentially effective for the protection of heart
from ischemia-reperfusion. Metabolomic results showed
that SA-B and propranolol had similar effects on meta-
bolic profiles of MI rats. The cell experiments
Figure 3 Effects of SA-B on H9C2 cell viability.
Figure 4 Effects of SA-B on the cellular calcium concentration
in H9C2 cells.* * P < 0.01 compared with anoxia.
Figure 5 Effects of SA-B on the levels of cAMP in H9C2 cells.
**P < 0.01 compared with anoxia.
Figure 6 Effects of SA-B on the PKA activity in H9C2 cell.* * P <
0.01 compared with anoxia.
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mainly by decreasing Ca
2+ and cAMP and inhibiting the
activation of PKA. This study indicates that SA-B and
propanolol might have a similar mechanism in treating
MI.
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